Cookson Peirce & Co. Inc. Cuts Stake in Sanofi (NASDAQ:SNY)

Cookson Peirce & Co. Inc. reduced its stake in Sanofi (NASDAQ:SNY) by 96.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,235 shares of the company’s stock after selling 484,123 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Sanofi were worth $758,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Rise Advisors LLC boosted its position in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after buying an additional 251 shares during the last quarter. SRS Capital Advisors Inc. boosted its position in shares of Sanofi by 289.1% during the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC purchased a new stake in shares of Sanofi during the third quarter valued at $26,000. Fairfield Bush & CO. purchased a new stake in shares of Sanofi during the first quarter valued at $26,000. Finally, Salem Investment Counselors Inc. purchased a new stake in shares of Sanofi during the fourth quarter valued at $27,000. 10.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Down 1.0 %

Shares of NASDAQ:SNY opened at $45.80 on Wednesday. The stock has a market capitalization of $115.86 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.73 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The stock’s 50-day simple moving average is $47.56 and its two-hundred day simple moving average is $48.71. Sanofi has a 52-week low of $42.63 and a 52-week high of $57.82.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. Analysts expect that Sanofi will post 4.16 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio (DPR) is 58.47%.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent analyst reports. Morgan Stanley initiated coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. TheStreet cut Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.